Aminophylline Infusion on Pain Intensity After Ureterocopic Lithotripsy
Aminophylline, Pain, Ureterocopic Lithotripsy
About this trial
This is an interventional treatment trial for Aminophylline focused on measuring Aminophylline, Postoperative Pain, Ureterocopic Lithotripsy
Eligibility Criteria
Inclusion Criteria: Aged between 18 to 50 years American society of anesthesiology (ASA) physical status I - II Body mass index (BMI) less than 30.0 kg/m2 Scheduled for ureteroscopic lithotripsy surgery with D-J ureteric stent placement at the end of procedure Under general anesthesia. Exclusion Criteria: Patients with central nervous system diseases, cardiovascular diseases, arrhythmias, cerebrovascular diseases, convulsions, renal impairment or hepatic dysfunction. Pregnancy or lactation. Patients with a history of allergy to aminophylline. Coffee consumption (more than 2 cups/day) Patients with opioid addiction or patients treated with B agonists, tranquilizers, or antidepressants. Short procedures less than 30 minutes or procedures not requiring D-J stent placement.
Sites / Locations
- Tanta University Hospitals
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Aminophylline group
Control group
Patients will receive 4 mg/kg aminophylline diluted in 100 ml normal saline over 20 minutes after induction of anesthesia and positioning of patients in lithotomy position.
Patients will receive 100 ml normal saline over 20 minutes after induction and lithotomy positioning.